Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Evogene (EVGN) over the last 14 years, with Q2 2025 value amounting to -$281.1 million.

  • Evogene's Retained Earnings fell 534.08% to -$281.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$281.1 million, marking a year-over-year decrease of 534.08%. This contributed to the annual value of -$274.1 million for FY2024, which is 639.98% down from last year.
  • As of Q2 2025, Evogene's Retained Earnings stood at -$281.1 million, which was down 534.08% from -$274.1 million recorded in Q4 2024.
  • In the past 5 years, Evogene's Retained Earnings ranged from a high of -$185.9 million in Q1 2021 and a low of -$281.1 million during Q2 2025
  • Over the past 5 years, Evogene's median Retained Earnings value was -$240.0 million (recorded in 2023), while the average stood at -$237.8 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 1669.91% in 2022, then tumbled by 534.08% in 2025.
  • Over the past 5 years, Evogene's Retained Earnings (Quarter) stood at -$207.1 million in 2021, then fell by 12.86% to -$233.7 million in 2022, then fell by 10.22% to -$257.6 million in 2023, then dropped by 6.4% to -$274.1 million in 2024, then fell by 2.57% to -$281.1 million in 2025.
  • Its Retained Earnings was -$281.1 million in Q2 2025, compared to -$274.1 million in Q4 2024 and -$274.5 million in Q3 2024.